Back to News
Market Impact: 0.4
FDA Accepts BridgeBio's Infigratinib NDA For Priority Review
Source: Nasdaq
Healthcare & BiotechRegulation & Legislation
The FDA accepted BridgeBio Pharma's New Drug Application for oral infigratinib to treat children with achondroplasia and granted it Priority Review. The decision advances the regulatory review but is not an approval.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
BBIO0.75
More News
- William Blair reiterates Outperform on BridgeBio Pharma stock
- Quantum BioPharma Ltd. (NASDAQ: QNTM) Enters Study Start-Up Agreement for Lucid-MS Phase 2 Trial
- Australia top court rules against coal mine expansion, citing climate harm
- Paramount's hard-fought takeover of Warner Bros. Discovery closes Tuesday. Here's how we got here
- Paramount and Warner Bros. Discovery complete $110 billion media megamerger
- Analysis-Vietnam’s banks tap investors for $7 billion as economy runs red hot
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Index and ETF Holdings Data for AI Research
- Capital Intensity as Gravity: The AI Trade Enters Its Industrial Era (Looking at Q3 2025 Earnings in Tech)